本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Vor Biopharma Inc.

25.00
-0.5000-1.96%
盘后25.000.00000.00%16:10 EDT
成交量:20.37万
成交额:508.56万
市值:1.71亿
市盈率:-0.07
高:25.56
开:25.16
低:24.59
收:25.50
52周最高:65.80
52周最低:2.62
股本:685.39万
流通股本:317.51万
量比:0.45
换手率:6.42%
股息:- -
股息率:- -
每股收益(TTM):-342.6591
每股收益(LYR):-34.0333
净资产收益率:-125.43%
总资产收益率:-121.29%
市净率:-0.11
市盈率(LYR):-0.73

数据加载中...

2025/07/15

关联方拟减持公告

Form 144 | VOR BIOPHARMA INC.高管 Robert Ang 拟减持214135股,总价约52万美元
2025/07/10

重要事件披露

Form 8-K - Current report
2025/07/10

关联方拟减持公告

Form 144 | VOR BIOPHARMA INC. 高管 Robert Ang 拟减持596885股,总价约138.8万美元
2025/07/03

关联方拟减持公告

Form 144 | VOR BIOPHARMA高管 Robert Ang 拟减持44936股,总价约8.04万美元
2025/07/01

关联方拟减持公告

Form 144 | VOR BIOPHARMA高管Robert Ang拟减持40468股,总价约69613美元
2025/06/30

关联方拟减持公告

Form 144 | VOR BIOPHARMA INC. 高管 Robert Ang 拟减持40627股,总价约70289美元
2025/06/26

重要事件披露

Form 8-K - Current report
2025/05/23

重要事件披露

Form 8-K - Current report
2025/05/21

重要事件披露

Form 8-K - Current report
2025/05/14

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/05/08

重要事件披露

Form 8-K - Current report
2025/04/25

重要事件披露

Form 8-K - Current report
2025/04/04

重要事件披露

Form 8-K - Current report
2025/03/28

SEC问询函

Form CORRESP - Correspondence
2025/03/20

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/03/20

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/02/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/02/10

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/02/06

重要事件披露

Form 8-K - Current report
2025/01/28

SEC问询函

Form CORRESP - Correspondence